Citadel Advisors
OACC

Citadel Advisors’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Citadel Advisors’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,253
Closed -$109K – 15187
2026
Q1 		$109K Buy
+10,253
New +$109K ﹤0.01% 11931
2025
Q2 		– Sell
-14,904
Closed -$152K – 15676
2025
Q1 		$152K Buy
+14,904
New +$150K ﹤0.01% 10855

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors's OACC Position: Q2 2026 in Review

Citadel Advisors sold out of Oaktree Acquisition Corp III Life Sciences (OACC) in Q2 2026, closing a stake of 10,253 shares — an estimated $109K sold.

Citadel Advisors first reported a position in OACC in Q1 2025 and held it in 2 quarters. The position peaked at $152K in Q1 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q2 2026.

  • Citadel Advisors reported no remaining Oaktree Acquisition Corp III Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 10,253 Oaktree Acquisition Corp III Life Sciences shares in Q2 2026, an estimated $109K.
  • Citadel Advisors first reported a position in Oaktree Acquisition Corp III Life Sciences in Q1 2025 and held it in 2 quarters.
  • Citadel Advisors's Oaktree Acquisition Corp III Life Sciences position peaked at $152K in Q1 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.